Iron, the substantia nigra and related neurological disorders

Biochimica et Biophysica Acta - General Subjects

Volumn 1790, Issue 7, 2009, Pages 606-614

  Snyder, Amanda M ^a   Connor, James R ^a  

^a PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

Author keywords

Parkinson's disease; Restless legs syndrome

Indexed keywords

DEFEROXAMINE; FERRIC CHLORIDE; FERRIC HYDROXIDE SUCROSE; FERRITIN; HFE PROTEIN; IRON; IRON DEXTRAN; LACTOFERRIN; MANEB; NEUROMELANIN; NEUROTOXIN; PARAQUAT; TRANSFERRIN RECEPTOR;

ALZHEIMER DISEASE; BLOOD BRAIN BARRIER; BRAIN REGION; DOPAMINERGIC NERVE CELL; DOPAMINERGIC SYSTEM; HUMAN; IRON STORAGE; IRON TRANSPORT; MICROGLIA; MOLECULAR MECHANICS; NEUROLOGIC DISEASE; NEUROPATHOLOGY; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN ANALYSIS; REGULATORY MECHANISM; RESTLESS LEGS SYNDROME; REVIEW; SUBSTANTIA NIGRA;

AGING; ANIMALS; APOFERRITINS; DISEASE MODELS, ANIMAL; FERRITINS; HISTOCOMPATIBILITY ANTIGENS CLASS I; IRON; MEMBRANE PROTEINS; MICROGLIA; PARKINSON DISEASE; RESTLESS LEGS SYNDROME; SUBSTANTIA NIGRA;

EID: 67349112729     PISSN: 03044165     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbagen.2008.08.005     Document Type: Review

References (143)

1. Gorell J.M., Ordidge R.J., Brown G.G., Deniau J.C., Buderer N.M., and Helpern J.A. Increased iron-related MRI contrast in the substantia nigra in Parkinson's disease. Neurology 45 (1995) 1138-1143
2. Bartzokis G., Cummings J.L., Markham C.H., Marmarelis P.Z., Treciokas L.J., Tishler T.A., Marder S.R., and Mintz J. MRI evaluation of brain iron in earlier- and later-onset Parkinson's disease and normal subjects. Magn. Reson. Imaging 17 (1999) 213-222
3. Schmidauer C., Sojer M., Seppi K., Stockner H., Hogl B., Biedermann B., Brandauer E., Peralta C.M., Wenning G.K., and Poewe W. Transcranial ultrasound shows nigral hypoechogenicity in restless legs syndrome. Ann. Neurol. 58 (2005) 630-634
4. Zecca L., Berg D., Arzberger T., Ruprecht P., Rausch W.D., Musicco M., Tampellini D., Riederer P., Gerlach M., and Becker G. In vivo detection of iron and neuromelanin by transcranial sonography: a new approach for early detection of substantia nigra damage. Mov. Disord. 20 (2005) 1278-1285
5. Drayer B., Burger P., Darwin R., Riederer S., Herfkens R., and Johnson G.A. MRI of brain iron. AJR Am. J. Roentgenol. 147 (1986) 103-110
6. Francois C., Nguyen-Legros J., and Percheron G. Topographical and cytological localization of iron in rat and monkey brains. Brain Res. 215 (1981) 317-322
7. Hill J.M., Ruff M.R., Weber R.J., and Pert C.B. Transferrin receptors in rat brain: neuropeptide-like pattern and relationship to iron distribution. Proc. Natl. Acad. Sci. U. S. A. 82 (1985) 4553-4557
8. Connor J.R., and Fine R.E. The distribution of transferrin immunoreactivity in the rat central nervous system. Brain Res. 368 (1986) 319-328
9. Sofic E., Paulus W., Jellinger K., Riederer P., and Youdim M.B. Selective increase of iron in substantia nigra zona compacta of parkinsonian brains. J. Neurochem. 56 (1991) 978-982
10. Connor J.R., Boyer P.J., Menzies S.L., Dellinger B., Allen R.P., Ondo W.G., and Earley C.J. Neuropathological examination suggests impaired brain iron acquisition in restless legs syndrome. Neurology 61 (2003) 304-309
11. Zecca L., Stroppolo A., Gatti A., Tampellini D., Toscani M., Gallorini M., Giaveri G., Arosio P., Santambrogio P., Fariello R.G., Karatekin E., Kleinman M.H., Turro N., Hornykiewicz O., and Zucca F.A. The role of iron and copper molecules in the neuronal vulnerability of locus coeruleus and substantia nigra during aging. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 9843-9848
12. Zucca F.A., Bellei C., Giannelli S., Terreni M.R., Gallorini M., Rizzio E., Pezzoli G., Albertini A., and Zecca L. Neuromelanin and iron in human locus coeruleus and substantia nigra during aging: consequences for neuronal vulnerability. J. Neural. Transm. 113 (2006) 757-767
13. Hallgren B., and Sourander P. The effect of age on the non-haemin iron in the human brain. J. Neurochem. 3 (1958) 41-51
14. Connor J.R., Menzies S.L., St Martin S.M., and Mufson E.J. Cellular distribution of transferrin, ferritin, and iron in normal and aged human brains. J. Neurosci. Res. 27 (1990) 595-611
15. Loeffler D.A., Connor J.R., Juneau P.L., Snyder B.S., Kanaley L., DeMaggio A.J., Nguyen H., Brickman C.M., and LeWitt P.A. Transferrin and iron in normal, Alzheimer's disease, and Parkinson's disease brain regions. J. Neurochem. 65 (1995) 710-724
16. Jones B.C., Reed C.L., Hitzemann R., Wiesinger J.A., McCarthy K.A., Buwen J.P., and Beard J.L. Quantitative genetic analysis of ventral midbrain and liver iron in BXD recombinant inbred mice. Nutr. Neurosci. 6 (2003) 369-377
17. Goodman Y., Bruce A.J., Cheng B., and Mattson M.P. Estrogens attenuate and corticosterone exacerbates excitotoxicity, oxidative injury, and amyloid beta-peptide toxicity in hippocampal neurons. J. Neurochem. 66 (1996) 1836-1844
18. Datla K.P., Murray H.E., Pillai A.V., Gillies G.E., and Dexter D.T. Difference in dopaminergic neuroprotective effects of estrogen during estrous cycle. NeuroReport 14 (2003) 47-50
19. Still C.N. Postmenopausal Parkinsonism: brain iron overload?. Adv. Exp. Med. Biol. 90 (1977) 291-296
20. Beard J.L., and Connor J.R. Iron status and neural functioning. Annu. Rev. Nutr. 23 (2003) 41-58
21. Chung, and Wessling R. Lessons learned from genetic and nutritional iron deficiencies. Nutr. Rev. 62 (2004) 212-215
22. Erikson K.M., Jones B.C., and Beard J.L. Iron deficiency alters dopamine transporter functioning in rat striatum. J. Nutr. 130 (2000) 2831-2837
23. Beard J.L., Unger E.L., Bianco L.E., Paul T., Rundle S.E., and Jones B.C. Early postnatal iron repletion overcomes lasting effects of gestational iron deficiency in rats. J. Nutr. 137 (2007) 1176-1182
24. Unger E.L., Paul T., Murray-Kolb L.E., Felt B., Jones B.C., and Beard J.L. Early iron deficiency alters sensorimotor development and brain monoamines in rats. J. Nutr. 137 (2007) 118-124
25. Nelson C., Erikson K., Pinero D.J., and Beard J.L. In vivo dopamine metabolism is altered in iron-deficient anemic rats. J. Nutr. 127 (1997) 2282-2288
26. Beard J.L., Wiesinger J.A., and Connor J.R. Pre- and postweaning iron deficiency alters myelination in Sprague-Dawley rats. Dev. Neurosci. 25 (2003) 308-315
27. Erikson K.M., Pinero D.J., Connor J.R., and Beard J.L. Regional brain iron, ferritin and transferrin concentrations during iron deficiency and iron repletion in developing rats. J. Nutr. 127 (1997) 2030-2038
28. Beard J., Erikson K.M., and Jones B.C. Neonatal iron deficiency results in irreversible changes in dopamine function in rats. J. Nutr. 133 (2003) 1174-1179
29. Burhans M.S., Dailey C., Wiesinger J., Murray-Kolb L.E., Jones B.C., and Beard J.L. Iron deficiency affects acoustic startle response and latency, but not prepulse inhibition in young adult rats. Physiol. Behav. 87 (2006) 917-924
30. Beard J.L., Felt B., Schallert T., Burhans M., Connor J.R., and Georgieff M.K. Moderate iron deficiency in infancy: biology and behavior in young rats. Behav. Brain Res. 170 (2006) 224-232
31. Burdo J.R., and Connor J.R. Brain iron uptake and homeostatic mechanisms: an overview. BioMetals 16 (2003) 63-75
32. Fisher J., Devraj K., Ingram J., Slagle-Webb B., Madhankumar A.B., Liu X., Klinger M., Simpson I.A., and Connor J.R. Ferritin: a novel mechanism for delivery of iron to the brain and other organs. Am. J. Physiol. Cell Physiol. 293 (2007) C641-649
33. Eisenstein R.S. Iron regulatory proteins and the molecular control of mammalian iron metabolism. Annu. Rev. Nutr. 20 (2000) 627-662
34. Mash D.C., Pablo J., Flynn D.D., Efange S.M., and Weiner W.J. Characterization and distribution of transferrin receptors in the rat brain. J. Neurochem. 55 (1990) 1972-1979
35. Morris C.M., Candy J.M., Omar S., Bloxham C.A., and Edwardson J.A. Transferrin receptors in the parkinsonian midbrain. Neuropathol. Appl. Neurobiol. 20 (1994) 468-472
36. Faucheux B.A., Hirsch E.C., Villares J., Selimi F., Mouatt-Prigent A., Javoy-Agid F., Hauw J.J., and Agid Y. Distribution of 125I-ferrotransferrin binding sites in the mesencephalon of control subjects and patients with Parkinson's disease. J. Neurochem. 60 (1993) 2338-2341
37. Hulet S.W., Menzies S., and Connor J.R. Ferritin binding in the developing mouse brain follows a pattern similar to myelination and is unaffected by the jimpy mutation. Dev. Neurosci. 24 (2002) 208-213
38. Hulet S.W., Hess E.J., Debinski W., Arosio P., Bruce K., Powers S., and Connor J.R. Characterization and distribution of ferritin binding sites in the adult mouse brain. J. Neurochem. 72 (1999) 868-874
39. Fillebeen C., Ruchoux M.M., Mitchell V., Vincent S., Benaissa M., and Pierce A. Lactoferrin is synthesized by activated microglia in the human substantia nigra and its synthesis by the human microglial CHME cell line is upregulated by tumor necrosis factor alpha or 1-methyl-4-phenylpyridinium treatment. Brain Res. Mol. Brain Res. 96 (2001) 103-113
40. Leveugle B., Faucheux B.A., Bouras C., Nillesse N., Spik G., Hirsch E.C., Agid Y., and Hof P.R. Cellular distribution of the iron-binding protein lactotransferrin in the mesencephalon of Parkinson's disease cases. Acta Neuropathol. 91 (1996) 566-572
41. Fillebeen C., Descamps L., Dehouck M.P., Fenart L., Benaissa M., Spik G., Cecchelli R., and Pierce A. Receptor-mediated transcytosis of lactoferrin through the blood-brain barrier. J. Biol. Chem. 274 (1999) 7011-7017
42. Faucheux B.A., Nillesse N., Damier P., Spik G., Mouatt-Prigent A., Pierce A., Leveugle B., Kubis N., Hauw J.J., Agid Y., et al. Expression of lactoferrin receptors is increased in the mesencephalon of patients with Parkinson disease. Proc. Natl. Acad. Sci. U. S. A. 92 (1995) 9603-9607
43. Dwork A.J., Lawler G., Zybert P.A., Durkin M., Osman M., Willson N., and Barkai A.I. An autoradiographic study of the uptake and distribution of iron by the brain of the young rat. Brain Res. 518 (1990) 31-39
44. Ferreira C., Bucchini D., Martin M.-E., Levi S., Arosio P., Grandchamp B., and Beaumont C. Early embryonic lethality of H ferritin gene deletion in mice. J. Biol. Chem. 275 (2000) 3021-3024
45. Levi S., Santambrogio P., Cozzi A., Rovida E., Corsi B., Tamborini E., Spada S., Albertini A., and Arosio P. The role of the L-chain in ferritin iron incorporation: studies of homo and heteropolymers. J. Mol. Biol. 238 (1994) 649-654
46. Lawson D.L., Treffry A., Artymiuk P.J., Harrison P.M., Yewdall S.J., Luzzago A., Cesareni G., Levi S., and Arosio P. Identification of the ferroxidase centre in ferritin. FEBS Lett. 254 (1989) 207-210
47. Connor J.R., Boeshore K.L., Benkovic S.A., and Menzies S.L. Isoforms of ferritin have a specific cellular distribution in the brain. J. Neurosci. Res. 37 (1994) 461-465
48. Connor J.R., Snyder B.S., Arosio P., Loeffler D.A., and LeWitt P. A quantitative analysis of isoferritins in select regions of aged, parkinsonian, and Alzheimer's diseased brains. J. Neurochem. 65 (1995) 717-724
49. Bartzokis G., Tishler T.A., Shin I.S., Lu P.H., and Cummings J.L. Brain ferritin iron as a risk factor for age at onset in neurodegenerative diseases. Ann. N. Y. Acad. Sci. 1012 (2004) 224-236
50. Sulzer D., Bogulavsky J., Larsen K.E., Behr G., Karatekin E., Kleinman M.H., Turro N., Krantz D., Edwards R.H., Greene L.A., and Zecca L. Neuromelanin biosynthesis is driven by excess cytosolic catecholamines not accumulated by synaptic vesicles. Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 11869-11874
51. Faucheux B.A., Martin M.E., Beaumont C., Hauw J.J., Agid Y., and Hirsch E.C. Neuromelanin associated redox-active iron is increased in the substantia nigra of patients with Parkinson's disease. J. Neurochem. 86 (2003) 1142-1148
52. Zecca L., Gallorini M., Schunemann V., Trautwein A.X., Gerlach M., Riederer P., Vezzoni P., and Tampellini D. Iron, neuromelanin and ferritin content in the substantia nigra of normal subjects at different ages: consequences for iron storage and neurodegenerative processes. J. Neurochem. 76 (2001) 1766-1773
53. Zecca L., Pietra R., Goj C., Mecacci C., Radice D., and Sabbioni E. Iron and other metals in neuromelanin, substantia nigra, and putamen of human brain. J. Neurochem. 62 (1994) 1097-1101
54. Double K.L., Gerlach M., Schunemann V., Trautwein A.X., Zecca L., Gallorini M., Youdim M.B., Riederer P., and Ben-Shachar D. Iron-binding characteristics of neuromelanin of the human substantia nigra. Biochem. Pharmacol. 66 (2003) 489-494
55. Herrero M.T., Hirsch E.C., Kastner A., Ruberg M., Luquin M.R., Laguna J., Javoy-Agid F., Obeso J.A., and Agid Y. Does neuromelanin contribute to the vulnerability of catecholaminergic neurons in monkeys intoxicated with MPTP?. Neuroscience 56 (1993) 499-511
56. Zecca L., Fariello R., Riederer P., Sulzer D., Gatti A., and Tampellini D. The absolute concentration of nigral neuromelanin, assayed by a new sensitive method, increases throughout the life and is dramatically decreased in Parkinson's disease. FEBS Lett. 510 (2002) 216-220
57. Halliday G.M., Del Tredici K., and Braak H. Critical appraisal of brain pathology staging related to presymptomatic and symptomatic cases of sporadic Parkinson's disease. J. Neural. Transm. Suppl. (2006) 99-103
58. Izumi Y., Sawada H., Yamamoto N., Kume T., Katsuki H., Shimohama S., and Akaike A. Iron accelerates the conversion of dopamine-oxidized intermediates into melanin and provides protection in SH-SY5Y cells. J. Neurosci. Res. 82 (2005) 126-137
59. Li J., Scheller C., Koutsilieri E., Griffiths F., Beart P.M., Mercer L.D., Halliday G.M., Kettle E., Rowe D., Riederer P., Gerlach M., Rodriguez M., and Double K.L. Differential effects of human neuromelanin and synthetic dopamine melanin on neuronal and glial cells. J. Neurochem. 95 (2005) 599-608
60. D'Amato R.J., Lipman Z.P., and Snyder S.H. Selectivity of the parkinsonian neurotoxin MPTP: toxic metabolite MPP+ binds to neuromelanin. Science 231 (1986) 987-989
61. D'Amato R.J., Alexander G.M., Schwartzman R.J., Kitt C.A., Price D.L., and Snyder S.H. Neuromelanin: a role in MPTP-induced neurotoxicity. Life Sci. 40 (1987) 705-712
62. D'Amato R.J., Alexander G.M., Schwartzman R.J., Kitt C.A., Price D.L., and Snyder S.H. Evidence for neuromelanin involvement in MPTP-induced neurotoxicity. Nature 327 (1987) 324-326
63. D'Amato R.J., Benham D.F., and Snyder S.H. Characterization of the binding of N-methyl-4-phenylpyridine, the toxic metabolite of the parkinsonian neurotoxin N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, to neuromelanin. J. Neurochem. 48 (1987) 653-658
64. Lindquist N.G., Larsson B.S., and Lyden-Sokolowski A. Autoradiography of [14C]paraquat or [14C]diquat in frogs and mice: accumulation in neuromelanin. Neurosci. Lett. 93 (1988) 1-6
65. Earley C.J., Allen R.P., Beard J.L., and Connor J.R. Insight into the pathophysiology of restless legs syndrome. J. Neurosci. Res. 62 (2000) 623-628
66. Allen R.P., and Earley C.J. Restless legs syndrome: a review of clinical and pathophysiologic features. J. Clin. Neurophysiol. 18 (2001) 128-147
67. Earley C.J., P B.B., Horska A., and Allen R.P. MRI-determined regional brain iron concentrations in early- and late-onset restless legs syndrome. Sleep Med. 7 (2006) 458-461
68. Allen R.P., Barker P.B., Wehrl F., Song H.K., and Earley C.J. MRI measurement of brain iron in patients with restless legs syndrome. Neurology 56 (2001) 263-265
69. Godau J., Schweitzer K.J., Liepelt I., Gerloff C., and Berg D. Substantia nigra hypoechogenicity: definition and findings in restless legs sydrome. Mov. Disord. 22 (2006) 187-192
70. Connor J.R., Wang X.S., Patton S.M., Menzies S.L., Troncoso J.C., Earley C.J., and Allen R.P. Decreased transferrin receptor expression by neuromelanin cells in restless legs syndrome. Neurology 62 (2004) 1563-1567
71. Earley C.J., Heckler D., and Allen R.P. The treatment of restless legs syndrome with intravenous iron dextran. Sleep Med. 5 (2004) 231-235
72. Earley C.J., Horska A., Mohamed M.A., Barker P.B., Beard J.L., and Allen R.P. A randomized, double-blind, placebo-controlled trial of intravenous iron sucrose in restless legs syndrome. Sleep Med. (2008)
73. Barton J.C., Wooten V.D., and Acton R.T. Hemochromatosis and iron therapy of restless legs syndrome. Sleep Med. 2 (2001) 249-251
74. Haba-Rubio J., Staner L., Petiau C., Erb G., Schunck T., and Macher J.P. Restless legs syndrome and low brain iron levels in patients with haemochromatosis. J. Neurol. Neurosurg. Psychiatry 76 (2005) 1009-1010
75. Nomura T., Inoue Y., and Nakashima K. Clinical characteristics of restless legs syndrome in patients with Parkinson's disease. J. Neurol. Sci. 250 (2006) 39-44
76. Gomez-Esteban J.C., Zarranz J.J., Tijero B., Velasco F., Barcena J., Rouco I., Lezcano E., Lachen M.C., Jauregui A., and Ugarte A. Restless legs syndrome in Parkinson's disease. Mov. Disord. 22 (2007) 1912-1916
77. Sofic E., Riederer P., Heinsen H., Beckmann H., Reynolds G.P., Hebenstreit G., and Youdim M.B. Increased iron (III) and total iron content in post mortem substantia nigra of parkinsonian brain. J. Neural. Transm. 74 (1988) 199-205
78. Dexter D.T., Wells F.R., Lees A.J., Agid F., Agid Y., Jenner P., and Marsden C.D. Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson's disease. J. Neurochem. 52 (1989) 1830-1836
79. Loeffler D.A., Connor J.R., Juneau P.L., Snyder B.S., Kanaley L., DeMaggio A.J., Nguyen H., Brickman C.M., and LeWitt P.A. Transferrin and iron in normal, Alzheimer's disease, and Parkinson's disease brain regions. J. Neurochem. 65 (1995) 710-716
80. Riederer P., Sofic E., Rausch W.D., Schmidt B., Reynolds G.P., Jellinger K., and Youdim M.B. Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains. J. Neurochem. 52 (1989) 515-520
81. Oakley A.E., Collingwood J.F., Dobson J., Love G., Perrott H.R., Edwardson J.A., Elstner M., and Morris C.M. Individual dopaminergic neurons show raised iron levels in Parkinson disease. Neurology 68 (2007) 1820-1825
82. Hirsch E.C., Breidert T., Rousselet E., Hunot S., Hartmann A., and Michel P.P. The role of glial reaction and inflammation in Parkinson's disease. Ann. N. Y. Acad. Sci. 991 (2003) 214-228
83. Zhang X., Surguladze N., Slagle-Webb B., Cozzi A., and Connor J.R. Cellular iron status influences the functional relationship between microglia and oligodendrocytes. Glia 54 (2006) 795-804
84. Connor J.R., and Menzies S.L. Altered cellular distribution of iron in the central nervous system of myelin deficient rats. Neuroscience 34 (1990) 265-271
85. Gelman B.B., Rodriguez-Wolf M.G., Wen J., Kumar S., Campbell G.R., and Herzog N. Siderotic cerebral macrophages in the acquired immunodeficiency syndrome. Arch. Pathol. Lab. Med. 116 (1992) 509-516
86. Dexter D.T., Carayon A., Vidailhet M., Ruberg M., Agid F., Agid Y., Lees A.J., Wells F.R., Jenner P., and Marsden C.D. Decreased ferritin levels in brain in Parkinson's disease. J. Neurochem. 55 (1990) 16-20
87. Faucheux B.A., Martin M.E., Beaumont C., Hunot S., Hauw J.J., Agid Y., and Hirsch E.C. Lack of up-regulation of ferritin is associated with sustained iron regulatory protein-1 binding activity in the substantia nigra of patients with Parkinson's disease. J. Neurochem. 83 (2002) 320-330
88. Faucheux B.A., Nillesse N., Damier P., Spik G., Mouatt-Prigent A., Pierce A., Leveugle B., Kubis N., Hauw J.J., Agid Y., and Hirsch E.C. Expression of lactoferrin receptors is increased in the mesencephalon of patients with Parkinson disease. Proc. Natl. Acad. Sci. U. S. A. 92 (1995) 9603-9607
89. Grau A.J., Willig V., Fogel W., and Werle E. Assessment of plasma lactoferrin in Parkinson's disease. Mov. Disord. 16 (2001) 131-134
90. Saint-Pierre M., Tremblay M.E., Sik A., Gross R.E., and Cicchetti F. Temporal effects of paraquat/maneb on microglial activation and dopamine neuronal loss in older rats. J. Neurochem. 98 (2006) 760-772
91. Fillebeen C., Mitchell V., Dexter D., Benaissa M., Beauvillain J., Spik G., and Pierce A. Lactoferrin is synthesized by mouse brain tissue and its expression is enhanced after MPTP treatment. Brain Res. Mol. Brain Res. 72 (1999) 183-194
92. Spillantini M.G., Schmidt M.L., Lee V.M., Trojanowski J.Q., Jakes R., and Goedert M. Alpha-synuclein in Lewy bodies. Nature 388 (1997) 839-840
93. Maroteaux L., Campanelli J.T., and Scheller R.H. Synuclein: a neuron-specific protein localized to the nucleus and presynaptic nerve terminal. J. Neurosci. 8 (1988) 2804-2815
94. Halliday G.M., Ophof A., Broe M., Jensen P.H., Kettle E., Fedorow H., Cartwright M.I., Griffiths F.M., Shepherd C.E., and Double K.L. Alpha-synuclein redistributes to neuromelanin lipid in the substantia nigra early in Parkinson's disease. Brain 128 (2005) 2654-2664
95. Castellani R.J., Siedlak S.L., Perry G., and Smith M.A. Sequestration of iron by Lewy bodies in Parkinson's disease. Acta Neuropathol. 100 (2000) 111-114
96. Golts N., Snyder H., Frasier M., Theisler C., Choi P., and Wolozin B. Magnesium inhibits spontaneous and iron-induced aggregation of alpha-synuclein. J. Biol. Chem. 277 (2002) 16116-16123
97. Uversky V.N., Li J., and Fink A.L. Metal-triggered structural transformations, aggregation, and fibrillation of human alpha-synuclein. A possible molecular NK between Parkinson's disease and heavy metal exposure. J. Biol. Chem. 276 (2001) 44284-44296
98. Borie C., Gasparini F., Verpillat P., Bonnet A.M., Agid Y., Hetet G., Brice A., Durr A., and Grandchamp B. Association study between iron-related genes polymorphisms and Parkinson's disease. J. Neurol. 249 (2002) 801-804
99. Ezquerra M., Campdelacreu J., Munoz E., and Tolosa E. Association study of the G258S transferrin gene polymorphism and Parkinson's disease in the Spanish population. J. Neurol. 252 (2005) 1269-1270
100. Lleo A., Blesa R., Angelopoulos C., Pastor-Rubio P., Villa M., Oliva R., and Bufill E. Transferrin C2 allele, haemochromatosis gene mutations, and risk for Alzheimer's disease. J. Neurol. Neurosurg. Psychiatry 72 (2002) 820-821
101. Feder J.N., Gnirke A., Thomas W., Tsuchihashi Z., Ruddy D.A., Basava A., Dormishian F., Domingo Jr. R., Ellis M.C., Fullan A., Hinton L.M., Jones N.L., Kimmel B.E., Kronmal G.S., Lauer P., Lee V.K., Loeb D.B., Mapa F.A., McClelland E., Meyer N.C., Mintier G.A., Moeller N., Moore T., Morikang E., Prass C.E., Quintana L., Starnes S.M., Schatzman R.C., Brunke K.J., Drayna D.T., Risch N.J., Bacon B.R., and Wolff R.K. A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. Nat. Genet. 13 (1996) 399-408
102. Connor J.R., and Lee S.Y. HFE mutations and Alzheimer's disease. J. Alzheimers Dis. 10 (2006) 267-276
103. Waheed A., Grubb J.H., Zhou X.Y., Tomatsu S., Fleming R.E., Costaldi M.E., Britton R.S., Bacon B.R., and Sly W.S. Regulation of transferrin-mediated iron uptake by HFE, the protein defective in hereditary hemochromatosis. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 3117-3122
104. Pulliam J.F., Jennings C.D., Kryscio R.J., Davis D.G., Wilson D., Montine T.J., Schmitt F.A., and Markesbery W.R. Association of HFE mutations with neurodegeneration and oxidative stress in Alzheimer's disease and correlation with APOE. Am. J. Med. Genet. B Neuropsychiatr. Genet. 119 (2003) 48-53
105. Goodall E.F., Greenway M.J., van Marion I., Carroll C.B., Hardiman O., and Morrison K.E. Association of the H63D polymorphism in the hemochromatosis gene with sporadic ALS. Neurology 65 (2005) 934-937
106. Wang X.S., Simmons Z., Liu W., Boyer P.J., and Connor J.R. Differential expression of genes in amyotrophic lateral sclerosis revealed by profiling the post mortem cortex. Amyotroph. Lateral. Scler. 7 (2006) 201-210
107. Costello D.J., Walsh S.L., Harrington H.J., and Walsh C.H. Concurrent hereditary haemochromatosis and idiopathic Parkinson's disease: a case report series. J. Neurol. Neurosurg. Psychiatry 75 (2004) 631-633
108. Guerreiro R.J., Bras J.M., Santana I., Januario C., Santiago B., Morgadinho A.S., Ribeiro M.H., Hardy J., Singleton A., and Oliveira C. Association of HFE common mutations with Parkinson's disease, Alzheimer's disease and mild cognitive impairment in a Portuguese cohort. BMC Neurol. 6 (2006) 24
109. Dekker M.C., Giesbergen P.C., Njajou O.T., van Swieten J.C., Hofman A., Breteler M.M., and van Duijn C.M. Mutations in the hemochromatosis gene (HFE), Parkinson's disease and parkinsonism. Neurosci. Lett. 348 (2003) 117-119
110. Akbas N., Hochstrasser H., Deplazes J., Tomiuk J., Bauer P., Walter U., Behnke S., Riess O., and Berg D. Screening for mutations of the HFE gene in Parkinson's disease patients with hyperechogenicity of the substantia nigra. Neurosci. Lett. 407 (2006) 16-19
111. Aamodt A.H., Stovner L.J., Thorstensen K., Lydersen S., White L.R., and Aasly J.O. Prevalence of haemochromatosis gene mutations in Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 78 (2007) 315-317
112. Buchanan D.D., Silburn P.A., Chalk J.B., Le Couteur D.G., and Mellick G.D. The Cys282Tyr polymorphism in the HFE gene in Australian Parkinson's disease patients. Neurosci. Lett. 327 (2002) 91-94
113. Gorell J.M., Johnson C.C., Rybicki B.A., Peterson E.L., Kortsha G.X., Brown G.G., and Richardson R.J. Occupational exposure to manganese, copper, lead, iron, mercury and zinc and the risk of Parkinson's disease. Neurotoxicology 20 (1999) 239-247
114. Logroscino G., Marder K., Graziano J., Freyer G., Slavkovich V., Lojacono N., Cote L., and Mayeux R. Dietary iron, animal fats, and risk of Parkinson's disease. Mov. Disord. 13 Suppl 1 (1998) 13-16
115. Powers K.M., Smith-Weller T., Franklin G.M., Longstreth Jr. W.T., Swanson P.D., and Checkoway H. Parkinson's disease risks associated with dietary iron, manganese, and other nutrient intakes. Neurology 60 (2003) 1761-1766
116. Uversky V.N. Neurotoxicant-induced animal models of Parkinson's disease: understanding the role of rotenone, maneb and paraquat in neurodegeneration. Cell Tissue Res. 318 (2004) 225-241
117. Levenson C.W., Cutler R.G., Ladenheim B., Cadet J.L., Hare J., and Mattson M.P. Role of dietary iron restriction in a mouse model of Parkinson's disease. Exp. Neurol. 190 (2004) 506-514
118. Kaur D., Peng J., Chinta S.J., Rajagopalan S., Di Monte D.A., Cherny R.A., and Andersen J.K. Increased murine neonatal iron intake results in Parkinson-like neurodegeneration with age. Neurobiol. Aging 28 (2007) 907-913
119. McCormack A.L., Thiruchelvam M., Manning-Bog A.B., Thiffault C., Langston J.W., Cory-Slechta D.A., and DiMonte D.A. Environmental risk factors and Parkinson's disease: selective degeneration of nigral dopaminergic neurons caused by the herbicide paraquat. Neurobiol. Dis. 10 (2002) 119-127
120. Peng J., Peng L., Stevenson F.F., Doctrow S.R., and Andersen J.K. Iron and paraquat as synergistic environmental risk factors in sporadic Parkinson's disease accelerate age-related neurodegeneration. J. Neurosci. 27 (2007) 6914-6922
121. Thomas C.E., and Aust S.D. Reductive release of iron from ferritin by cation free radicals of paraquat and other bipyridyls. J. Biol. Chem. 261 (1986) 13064-13070
122. Robb S.J., Robb-Gaspers L.D., Scaduto Jr. R.C., Thomas A.P., and Connor J.R. Influence of calcium and iron on cell death and mitochondrial function in oxidatively stressed astrocytes. J. Neurosci. Res. 55 (1999) 674-686
123. Robb S.J., and Connor J.R. An in vitro model for analysis of oxidative death in primary mouse astrocytes. Brain Res. 788 (1998) 125-132
124. Zhang J., Fitsanakis V.A., Gu G., Jing D., Ao M., Amarnath V., and Montine T.J. Manganese ethylene-bis-dithiocarbamate and selective dopaminergic neurodegeneration in rat: a link through mitochondrial dysfunction. J. Neurochem. 84 (2003) 336-346
125. Barlow B.K., Lee D.W., Cory-Slechta D.A., and Opanashuk L.A. Modulation of antioxidant defense systems by the environmental pesticide maneb in dopaminergic cells. Neurotoxicology 26 (2005) 63-75
126. Thiruchelvam M., McCormack A., Richfield E.K., Baggs R.B., Tank A.W., Di Monte D.A., and Cory-Slechta D.A. Age-related irreversible progressive nigrostriatal dopaminergic neurotoxicity in the paraquat and maneb model of the Parkinson's disease phenotype. Eur. J. Neurosci. 18 (2003) 589-600
127. Thiruchelvam M., Richfield E.K., Baggs R.B., Tank A.W., and Cory-Slechta D.A. The nigrostriatal dopaminergic system as a preferential target of repeated exposures to combined paraquat and maneb: implications for Parkinson's disease. J. Neurosci. 20 (2000) 9207-9214
128. Zhang Z.X., Anderson D.W., Huang J.B., Li H., Hong X., Wei J., Yang E.L., and Maraganore D.M. Prevalence of Parkinson's disease and related disorders in the elderly population of greater Beijing, China. Mov. Dis. 18 (2003) 764-772
129. Thiruchelvam M., Brockel B.J., Richfield E.K., Baggs R.B., and Cory-Slechta D.A. Potentiated and preferential effects of combined paraquat and maneb on nigrostriatal dopamine systems: environmental risk factors for Parkinson's disease?. Brain Res. 873 (2000) 225-234
130. Ben-Shachar D., and Youdim M.B. Intranigral iron injection induces behavioral and biochemical "parkinsonisn" in rats. J. Neurochem. 57 (1991) 2133-2135
131. Thompson K., Menzies S., Muckenthaler M., Torti F.M., Wood T., Torti S.V., Hentze M.W., Beard J., and Connor J. Mouse brains deficient in H-ferritin have normal iron concentration but a protein profile of iron deficiency and increased evidence of oxidative stress. J. Neurosci. Res. 71 (2003) 46-63
132. Kaur D., Yantiri F., Rajagopalan S., Kumar J., Mo J.Q., Boonplueang R., Viswanath V., Jacobs R., Yang L., Beal M.F., DiMonte D., Volitaskis I., Ellerby L., Cherny R.A., Bush A.I., and Andersen J.K. Genetic or pharmacological iron chelation prevents MPTP-induced neurotoxicity in vivo: a novel therapy for Parkinson's disease. Neuron 37 (2003) 899-909
133. Grabill C., Silva A.C., Smith S.S., Koretsky A.P., and Rouault T.A. MRI detection of ferritin iron overload and associated neuronal pathology in iron regulatory protein-2 knockout mice. Brain Res. 971 (2003) 95-106
134. LaVaute T., Smith S., Cooperman S., Iwai K., Land W., Meyron-Holtz E., Drake S.K., Miller G., Abu-Asab M., Tsokos M., Switzer III R., Grinberg A., Love P., Tresser N., and Rouault T.A. Targeted deletion of the gene encoding iron regulatory protein-2 causes misregulation of iron metabolism and neurodegenerative disease in mice. Nat. Genet. 27 (2001) 209-214
135. Galy B., Holter S.M., Klopstock T., Ferring D., Becker L., Kaden S., Wurst W., Grone H.-J., and Hentze M.W. Iron homeostasis in the brain: complete iron regulatory protein 2 deficiency without sympotmatic neurodegeneration in the mouse. Nat. Genet. 38 (2006) 967-969
136. Galy B., Ferring D., and Hentze M.W. Generation of conditional alleles of the murine Iron Regulatory Protein (IRP)-1 and -2 genes. Genesis 43 (2005) 181-188
137. Salvatore M.F., Fisher B., Surgener S.P., Gerhardt G.A., and Rouault T. Neurochemical investigations of dopamine neuronal systems in iron-regulatory protein 2 (IRP-2) knockout mice. Brain Res. Mol. Brain Res. 139 (2005) 341-347
138. Meyron-Holtz E.G., Ghosh M.C., Iwai K., LaVaute T., Brazzolotto X., Berger U.V., Land W., Ollivierre-Wilson H., Grinberg A., Love P., and Rouault T.A. Genetic ablations of iron regulatory proteins 1 and 2 reveal why iron regulatory protein 2 dominates iron homeostasis. EMBO J. 23 (2004) 386-395
139. Galy B., Ferring D., Minana B., Bell O., Janser H.G., Muckenthaler M., Schumann K., and Hentze M.W. Altered body iron distribution and microcytosis in mice deficient in iron regulatory protein 2 (IRP2). Blood 106 (2005) 2580-2589
140. Lin L.F., Doherty D.H., Lile J.D., Bektesh S., and Collins F. GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. Science 260 (1993) 1130-1132
141. Purisai M.G., McCormack A.L., Cumine S., Li J., Isla M.Z., and Di Monte D.A. Microglial activation as a priming event leading to paraquat-induced dopaminergic cell degeneration. Neurobiol. Dis. 25 (2007) 392-400
142. Wu D.C., Jackson-Lewis V., Vila M., Tieu K., Teismann P., Vadseth C., Choi D.K., Ischiropoulos H., and Przedborski S. Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson disease. J. Neurosci. 22 (2002) 1763-1771
143. McGeer P.L., Itagaki S., Boyes B.E., and McGeer E.G. Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology 38 (1988) 1285-1291